Bio-Path Holdings shares are trading higher Thursday after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.
Wedbush analyst Alicia Reese maintained AMC with a Neutral rating and cut the price target from $6 to $4. Interestingly enough, the analyst actually raised estimates for the first quarter, citing better box office trends.